Form 4: Protara Therapeutics Director, Jane Huang, Acquires 10,000 Stock Options
SEC Form 4
Director Jane Huang acquired 10,000 stock options in Protara Therapeutics, Inc. on June 7, 2024.
Summary
- On June 7, 2024, Jane Huang, a director of Protara Therapeutics, Inc., acquired 10,000 stock options.
- The exercise price of these options is $2.67.
- The options vest in equal monthly installments over 12 months, with full vesting by the next annual stockholder meeting or upon a Change of Control, contingent on continuous service as a board member.
- The options expire on June 6, 2034.
- Following the transaction, Jane Huang directly owns 10,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing a stock option grant. It doesn't inherently convey positive or negative sentiment.
Industry Context
This is a standard disclosure related to insider transactions, common in the pharmaceutical industry where stock options are frequently used as part of director compensation.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder confidence, as it indicates a director's belief in the company's future.
Key Dates
| Date | Description |
|---|---|
| 06/07/2024 | Date of stock option acquisition |
| 06/06/2034 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.